GC Biopharma Selected for Korea's COVID-19 mRNA Vaccine Phase 1 Clinical Trial Support Program
核心洞察
GC Biopharma (搜索) has been selected as one of only two companies to receive support for phase 1 clinical trials in Korea's pandemic preparedness mRNA vaccine development program.
The company is positioned as the only Korean firm capable of handling the entire mRNA vaccine development process from candidate selection to manufacturing using its proprietary mRNA-LNP platform.
GC Biopharma (搜索) aims to obtain IND approval for its COVID-19 (搜索) mRNA vaccine candidate within this year and plans to submit phase 2 clinical trial applications in the second half of 2026.
GC Biopharma (搜索) has been selected as one of only two companies to advance to phase 1 clinical trials under Korea's pandemic preparedness mRNA vaccine development support program, the company announced on December 15. The Korea Centers for Disease Control and Prevention (搜索) organized the initiative to establish domestic mRNA vaccine capabilities for rapid pandemic response.
Exclusive Platform Capabilities
The selection process narrowed four companies from the non-clinical stage to just two for clinical phase 1 trial support. GC Biopharma (搜索) distinguished itself as the only Korean company capable of independently managing the complete vaccine development pipeline, from candidate material derivation through manufacturing and production, using its proprietary mRNA and lipid nanoparticle (搜索) (LNP) platform.
The company's platform competitiveness stems from several key technologies, including UTR patents, artificial intelligence-based codon optimization, and LNP technology designed to enhance delivery efficiency. These capabilities position GC Biopharma (搜索) uniquely within Korea's biotechnology landscape for mRNA vaccine development.
Clinical Development Timeline
GC Biopharma (搜索) has set an ambitious timeline for its COVID-19 (搜索) mRNA vaccine candidate, targeting IND approval within this year. Following regulatory approval, the company plans to accelerate research activities and submit phase 2 clinical trial applications in the second half of 2026.
The accelerated development schedule reflects both the company's confidence in its platform technology and the strategic importance of establishing domestic vaccine manufacturing capabilities.
National Pandemic Preparedness Strategy
"Securing a domestic mRNA vaccine platform is an important task to strengthen national quarantine capabilities," said Jeong Jae-wook, head of GC Biopharma (搜索)'s R&D division. The executive emphasized that the company would use this opportunity to further accelerate development speed and contribute substantially to the national quarantine system.
The program represents Korea's strategic investment in pandemic preparedness infrastructure, ensuring the country can respond quickly to future health emergencies through domestic vaccine production capabilities rather than relying solely on international suppliers.